(NASDAQ: FTRE) Fortrea Holdings's forecast annual revenue growth rate of 1.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Fortrea Holdings's revenue in 2025 is $2,759,900,000.On average, 14 Wall Street analysts forecast FTRE's revenue for 2025 to be $257,056,800,000, with the lowest FTRE revenue forecast at $245,414,400,000, and the highest FTRE revenue forecast at $266,666,400,000. On average, 14 Wall Street analysts forecast FTRE's revenue for 2026 to be $257,149,200,000, with the lowest FTRE revenue forecast at $236,174,400,000, and the highest FTRE revenue forecast at $271,656,000,000.
In 2027, FTRE is forecast to generate $264,541,200,000 in revenue, with the lowest revenue forecast at $242,272,800,000 and the highest revenue forecast at $282,559,200,000.